Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
IOBT Stock Chart & Stats
$0.37
-$0.03(-3.11%)
At close: 4:00 PM EST
$0.37
-$0.03(-3.11%)
Day’s Range― - ―
52-Week Range$0.21 - $2.79
Previous CloseN/A
Volume57.25K
Average Volume (3M)18.93M
Market Cap
$26.41M
Enterprise Value-$3.32M
Total Cash (Recent Filing)$30.66M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding71,948,845
10 Day Avg. Volume2,545,950
30 Day Avg. Volume18,930,692
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.74
Enterprise Value/Market Cap-0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$0.43Price Target Upside16.22% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 data demonstrated meaningful improvement in progression-free and overall survival when Cylembio was combined with standard therapy, supporting the drug's potential clinical value across indications.
Indication-specific StrengthFinal Phase 2 basket results showed particularly strong benefit in head and neck cancer, which could justify a focused development path and a differentiated commercial opportunity.
Regulatory EngagementA scheduled meeting with the FDA to discuss Phase 3 trial design could clarify approval requirements and increase the likelihood of a successful registrational strategy for Cylembio.
Bears Say
Financing And Partnership RiskAdvancing a new registrational trial will likely require additional capital or external partnerships, increasing dilution risk or strategic dependency for the company.
Program Delay RiskThe regulatory recommendation to redesign the registrational program is likely to require a new Phase 3 study, introducing a multi-year delay before potential US approval.
Regulatory SetbackThe FDA previously advised against submitting a biologics license application after a Phase 3 outcome narrowly missed its primary endpoint, creating uncertainty around the approval pathway.
IO Biotech News
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.20 and its highest was $2.79 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $26.41M.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is May 19, 2026 which is in 96 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Nov 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.324 by $0.194.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IO Biotech have?
IO Biotech has 71,948,845 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.324. Following the earnings report the stock price went up 1.722%.
Which hedge fund is a major shareholder of IO Biotech?
Currently, no hedge funds are holding shares in IOBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IO Biotech
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
IOBT Stock 12 Month Forecast
Average Price Target
$0.43
▲(16.22% Upside)
Technical Analysis
Ownership Overview
19.72% Insiders
0.15% Mutual Funds
5.95% Other Institutional Investors
74.18% Public Companies and Individual Investors
Options Prices
Currently, No data available
---